AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11450724 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone canalicular plugs
Number of subjects: 44
Study 11450724 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 44
Study 9589647 — intervention group
Group type: COMPARATOR
Intervention: rhLH 0 IU/day
Number of subjects: 38
Study 9589647 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLH 25 IU/day
Number of subjects: 38
Study 9589647 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLH 75 IU/day
Number of subjects: 38
Study 9589647 — intervention group
Group type: EXPERIMENTAL
Intervention: rhLH 225 IU/day
Number of subjects: 38
Study 7999526 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 152
Study 7999526 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 152
Study 3072307 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin preparation for 12 days
Number of subjects: 66
Study 3072307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31656978 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 33% de-oiled rice bran (DORB)
Number of subjects: 180
Study 31656978 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 38% de-oiled rice bran (DORB)
Number of subjects: 180
Study 31656978 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 43% de-oiled rice bran (DORB)
Number of subjects: 180
Study 31656978 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 53% de-oiled rice bran (DORB)
Number of subjects: 180
Study 31656978 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 58% de-oiled rice bran (DORB)
Number of subjects: 180
Study 29427691 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal pasta (117g)
Number of subjects: 14
Study 29427691 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat pasta (100g)
Number of subjects: 14
Study 28626756 — intervention group
Group type: EXPERIMENTAL
Intervention: MyrLiq 400 mg/day
Number of subjects: 184
Study 28626756 — intervention group
Group type: EXPERIMENTAL
Intervention: MyrLiq 200 mg/day
Number of subjects: 184
Study 28626756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 24330826 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25 mg/day p.o.) with immediate substitution
Number of subjects: 0
Study 24330826 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25 mg/day p.o.) with short-tapering of previous drug
Number of subjects: 0
Study 24330826 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25 mg/day p.o.) with long-tapering of previous drug
Number of subjects: 0
Study 22801472 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (3 hours of arm training per day)
Number of subjects: 32
Study 22801472 — intervention group
Group type: COMPARATOR
Intervention: Group A (1 hour of arm training per day)
Number of subjects: 32
Study 22801472 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (2 hours of arm training per day)
Number of subjects: 32
Study 22801472 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 32
Study 21365213 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 24
Study 18441708 — intervention group
Group type: EXPERIMENTAL
Intervention: monopril + propranolol + heparin
Number of subjects: 50
Study 18441708 — intervention group
Group type: COMPARATOR
Intervention: propranolol + heparin
Number of subjects: 50
Study 12612990 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral nutritional supplement 2 hours before lunch
Number of subjects: 13
Study 12612990 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink 30 minutes before lunch
Number of subjects: 13
Study 12612990 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral nutritional supplement 30 minutes before lunch
Number of subjects: 13
Study 9923328 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 82
Study 9923328 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation
Number of subjects: 82
Study 7899060 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced MRI (superparamagnetic iron oxide); pulse sequences: SE 500/20 (T1WI), SE 2000/20 (PDWI), SE 2000/70 (T2WI); contrast medium dose: 10 mumoles Fe/kg, administered intravenously for more than 30 minutes.
Number of subjects: 17
Study 7899060 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced MRI; pulse sequences: SE 500/20 (T1WI), SE 2000/20 (PDWI), SE 2000/70 (T2WI).
Number of subjects: 17
Study 7899060 — intervention group
Group type: COMPARATOR
Intervention: Helical CT.
Number of subjects: 17
Study 2559272 — intervention group
Group type: EXPERIMENTAL
Intervention: DTC 200 mg/m2 intravenously weekly for 16 weeks
Number of subjects: 40
Study 2559272 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 40
Study 352709 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 20
Study 352709 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine 25 mg
Number of subjects: 20
Study 352709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31507293 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced, implementer, optimizer, and random assignment team formation methods
Number of subjects: 237
Study 28251894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermocosmetic treatment (containing lipohydroxyacid, nicotinamide, and piroctone-olamine)
Number of subjects: 32
Study 28251894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25712456 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus bevacizumab (bev)
Number of subjects: 0
Study 25712456 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab (bev)
Number of subjects: 0
Study 23474581 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary technique (Group A)
Number of subjects: 216
Study 23474581 — intervention group
Group type: COMPARATOR
Intervention: Hybrid technique (Group B)
Number of subjects: 216
Study 21099447 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal ω‐3 fatty acid supplementation (1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid)
Number of subjects: 0
Study 21099447 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal ω‐3 fatty acid supplementation
Number of subjects: 0
Study 21099447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19221150 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with prophylactic cranial irradiation
Number of subjects: 8779
Study 19221150 — intervention group
Group type: COMPARATOR
Intervention: First-line chemotherapy without prophylactic cranial irradiation
Number of subjects: 8779
Study 16754835 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 110
Study 16754835 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 110
Study 16754835 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 110
Study 15016252 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF(2)-containing toothpaste and mouthrinse
Number of subjects: 96
Study 11699054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis patients (n = 38)
Number of subjects: 38
Study 11699054 — intervention group
Group type: COMPARATOR
Intervention: Controls with normal liver function (n = 29)
Number of subjects: 38
Study 9174558 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (5000 IU bd)
Number of subjects: 19435
Study 9174558 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (12,500 IU bd)
Number of subjects: 19435
Study 9174558 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily)
Number of subjects: 19435
Study 9174558 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 19435
Study 8198237 — intervention group
Group type: EXPERIMENTAL
Intervention: Open challenge with food additives (coloring agents, preservatives, citric acid, flavoring agents) using carbonated lemonade; two doses: low dose and 10-fold higher dose.
Number of subjects: 335
Study 8198237 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind challenge with food additives (preservatives, coloring agents, citric acid) using gelatin capsules.
Number of subjects: 335
Study 8198237 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with atopic skin symptoms (asthma, atopic dermatitis, rhinitis, urticaria).
Number of subjects: 335
Study 29609646 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body-radiotherapy (SBRT) boost dose of 18 Gy
Number of subjects: 0
Study 29609646 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body-radiotherapy (SBRT) boost dose of 21 Gy
Number of subjects: 0
Study 29609646 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body-radiotherapy (SBRT) boost (both doses)
Number of subjects: 0
Study 26671303 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 292
Study 26671303 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 292
Study 26671303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 292
Study 23857438 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC positioned in the right atrium (group A)
Number of subjects: 60
Study 23857438 — intervention group
Group type: COMPARATOR
Intervention: CVC positioned in the superior vena cava (group C)
Number of subjects: 60
Study 22784661 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Technique applied by nurses (four-session protocol)
Number of subjects: 122
Study 22784661 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided to caregivers
Number of subjects: 122
Study 20135172 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy and common bile duct exploration at the same sitting
Number of subjects: 30
Study 20135172 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic stone clearance followed by laparoscopic cholecystectomy 4‐6 weeks later
Number of subjects: 30
Study 19672410 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient particles (CAPs) + O(3)
Number of subjects: 50
Study 19672410 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient particles (CAPs)
Number of subjects: 50
Study 19672410 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 50
Study 19672410 — intervention group
Group type: COMPARATOR
Intervention: O(3)
Number of subjects: 50
Study 19672410 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CAPs and O(3)
Number of subjects: 50
Study 16373066 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 141
Study 16373066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 12723011 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized follow-up intervention (including reminder letters and phone calls if no appointment was made within 10 days)
Number of subjects: 132
Study 12723011 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up intervention (reminder letters only)
Number of subjects: 132
Study 10985216 — intervention group
Group type: EXPERIMENTAL
Intervention: bactrim
Number of subjects: 0
Study 10985216 — intervention group
Group type: COMPARATOR
Intervention: aerosolized pentamidine (AP)
Number of subjects: 0
Study 9120932 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antiandrogen (nilutamide)
Number of subjects: 868
Study 9120932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 868
Study 8312689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5
Study 8312689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3714619 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alpha- and beta-blockade (labetalol)
Number of subjects: 10
Study 3714619 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockade alone (propranolol)
Number of subjects: 10
Study 30157955 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV + sigh
Number of subjects: 129
Study 30157955 — intervention group
Group type: COMPARATOR
Intervention: Standard PSV
Number of subjects: 129
Study 27586458 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Agents (WAJA)
Number of subjects: 30
Study 25083601 — intervention group
Group type: EXPERIMENTAL
Intervention: START (manualised coping skills intervention)
Number of subjects: 260
Study 25083601 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 260
Study 22055330 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) for 8 weeks
Number of subjects: 90
Study 22055330 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus SSRIs
Number of subjects: 90
Study 19896202 — intervention group
Group type: EXPERIMENTAL
Intervention: Online LCM (Life Chart Methodology)
Number of subjects: 48
Study 19896202 — intervention group
Group type: COMPARATOR
Intervention: Standard paper LCM
Number of subjects: 48
Study 18380940 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination (twice before surgery or conservative treatment)
Number of subjects: 40
Study 18380940 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated surgical patients
Number of subjects: 40
Study 18380940 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated surgical patients
Number of subjects: 40
Study 16034289 — intervention group
Group type: EXPERIMENTAL
Intervention: Shelter-based intervention including intensive outreach by a psychiatric social worker and availability of weekly psychiatrist visits
Number of subjects: 102
Study 16034289 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 102
Study 12464463 — intervention group
Group type: EXPERIMENTAL
Intervention: 14‐mg nicotine patch
Number of subjects: 29
Study 10234601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprescription ibuprofen (800 to 1200 mg/day for 1 to 10 days)
Number of subjects: 2187
Study 10234601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2187
Study 10234601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprescription ibuprofen
Number of subjects: 2187
Study 7795325 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling format A (informed antibiotics are safe)
Number of subjects: 138
Study 7795325 — intervention group
Group type: COMPARATOR
Intervention: Counseling format B (informed antibiotics are safe and about theoretical risk of diarrhea)
Number of subjects: 138
Study 7795325 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling format A
Number of subjects: 138
Study 7795325 — intervention group
Group type: COMPARATOR
Intervention: Counseling format B
Number of subjects: 138
Study 7795325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 138
Study 1674104 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic-antagonist treatment (propranolol in 203 patients and nadolol in 83 patients)
Number of subjects: 589
Study 1674104 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 589
Study 6795245 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (mean dose, 3.1 mg/day)
Number of subjects: 0
Study 6795245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (mean dose, 1150 mg/day)
Number of subjects: 0
Study 6795245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31751170 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized online weight loss intervention
Number of subjects: 15
Study 28661822 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment for substance abuse disorder
Number of subjects: 190
Study 25374101 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU insulin detemir
Number of subjects: 60
Study 25374101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23371384 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based risk appraisal tool
Number of subjects: 15495
Study 23371384 — intervention group
Group type: COMPARATOR
Intervention: Control group (no web-based tool)
Number of subjects: 15495
Study 21340475 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment (mean dose 2.69 mg, mean duration 3.1 years)
Number of subjects: 51
Study 21340475 — intervention group
Group type: COMPARATOR
Intervention: Control group (general Dutch population of the same age and sex)
Number of subjects: 51
Study 18823687 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Low-Sodium (LS) diet
Number of subjects: 34
Study 18823687 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/High Sodium
Number of subjects: 34
Study 18823687 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/Low Sodium (LS)
Number of subjects: 34
Study 18823687 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/High Sodium plus Hydrochlorothiazide (HCT)
Number of subjects: 34
Study 18823687 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/Low Sodium (LS) plus Hydrochlorothiazide (HCT)
Number of subjects: 34
Study 18823687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Losartan plus HCT
Number of subjects: 34
Study 17381182 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 15346093 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 78
Study 15346093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 10907116 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-load glucose concentrations
Number of subjects: 385
Study 10907116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting split proinsulin and 30-min insulin concentrations
Number of subjects: 385
Study 10907116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting, split proinsulin and 30-min insulin concentrations
Number of subjects: 385
Study 10907116 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma glucose 30 min after a glucose load
Number of subjects: 385
Study 10907116 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin concentrations
Number of subjects: 385
Study 9278939 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 9
Study 9278939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8317386 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine oil supplementation
Number of subjects: 0
Study 8317386 — intervention group
Group type: COMPARATOR
Intervention: Standard formulas (control)
Number of subjects: 0
Study 3105412 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanone suture (PDS) for colonic anastomoses
Number of subjects: 98
Study 3105412 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture material (silk) for colonic anastomoses
Number of subjects: 98
Study 3105412 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanone suture (PDS) for gastric or small bowel anastomoses
Number of subjects: 98
Study 3105412 — intervention group
Group type: COMPARATOR
Intervention: Chromic catgut for gastric or small bowel anastomoses
Number of subjects: 98
Study 29671705 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPP version 2 criteria
Number of subjects: 206
Study 29671705 — intervention group
Group type: COMPARATOR
Intervention: Clinician's application of STOPP version 2
Number of subjects: 206
Study 29671705 — intervention group
Group type: EXPERIMENTAL
Intervention: STOPP version 2 criteria (systematic application)
Number of subjects: 206
Study 29671705 — intervention group
Group type: COMPARATOR
Intervention: Clinician's implicit evaluation
Number of subjects: 206
Study 31176205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant IMRT
Number of subjects: 52
Study 31176205 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 27196566 — intervention group
Group type: EXPERIMENTAL
Intervention: PSAs with integrated affirming text
Number of subjects: 0
Study 27196566 — intervention group
Group type: COMPARATOR
Intervention: PSAs without affirming text
Number of subjects: 0
Study 25981810 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sonidegib
Number of subjects: 230
Study 25981810 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg sonidegib
Number of subjects: 230
Study 24173657 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine hydrochloride extended release (up to 300 mg)
Number of subjects: 21
Study 24173657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine hydrochloride (up to 80 mg)
Number of subjects: 21
Study 21188415 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral (UL) maximal voluntary contraction (MVC)
Number of subjects: 13
Study 21188415 — intervention group
Group type: COMPARATOR
Intervention: Bilateral (BL) maximal voluntary contraction (MVC)
Number of subjects: 13
Study 21188415 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 13
Study 19295417 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support intervention 1 week after surgery
Number of subjects: 228
Study 19295417 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study 17180156 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐dialytic parenteral nutrition (IDPN) with exercise
Number of subjects: 5
Study 17180156 — intervention group
Group type: COMPARATOR
Intervention: Intra‐dialytic parenteral nutrition (IDPN) alone
Number of subjects: 5
Study 15084858 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin 0.5%
Number of subjects: 67
Study 15084858 — intervention group
Group type: EXPERIMENTAL
Intervention: ofloxacin 0.3%
Number of subjects: 67
Study 15084858 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin 0.3%
Number of subjects: 67
Study 11997706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine D2-class receptor antagonist sulpiride
Number of subjects: 0
Study 9602581 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1 MAC)
Number of subjects: 25
Study 9602581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.1 MAC)
Number of subjects: 25
Study 9602581 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (0.1 MAC)
Number of subjects: 25